The Southwest Oncology Group (SWOG) is one of the largest cancer clinical trials groups in the United States. Funded by research grants from the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), the Group’s network consists of more than 5,000 physician-researchers practicing at nearly 550 institutions across the United States and Canada. For more than 50 years the Southwest Oncology Group has played a key role in the development of new treatments for cancer.

For additional information regarding publications, please contact:
SWOG Publications Manager
24 Frank Lloyd Wright Drive, P.O. Box 483
Ann Arbor, MI 48106-0483
734-998-7187
pubs@swog.org

Note that this document is not an official ASCO publication.

ASCO-ACCEPTED ABSTRACTS BY DISEASE SITE

Brain

S9811
Southwest Oncology Group S9811: a phase II study of hydroxyurea for unresectable meningioma.
LJ Swinnen, C Rankin, EJ Rushing, HF Laura, DM Damek, GR Barger.
Accepted to the ASCO Annual Meeting Proceedings as a general poster.
SUNDAY, MAY 31, 8:00 AM – 12:00 PM, LEVEL 2, WEST HALL C
Poster no. C13, Abstract no. 2063

Gastrointestinal

S0356
Oxaliplatin (OXP) plus protracted infusion 5-fluorouracil (PIFU) and external beam radiation (EBRT) prior to surgery (S) for potentially curable esophageal adenocarcinoma (EA): a Southwest Oncology Group (SWOG) phase II trial with molecular correlates (S0356).
L Leichman, B Goldman, J Benedetti, K Billingsley, C Thomas, S Iqbal, HJ Lenz, CD Blanke, P Gold, C Corless.
Accepted to the ASCO Annual Meeting Proceedings as a poster discussion.
SUNDAY, MAY 31, 5:00 – 6:00 PM, LEVEL 2, WEST HALL D1
Poster no. 2, Abstract no. 4513

S9008
Chemoradiation of resected gastric cancer: a 10 year follow-up of INT0116 (SWOG 9008).
Accepted to the ASCO Annual Meeting Proceedings as a poster discussion.
SUNDAY, MAY 31, 5:00 – 6:00 PM, LEVEL 2, WEST HALL D1
Poster no. 4, Abstract no. 4515
**Genitourinary**

S0354
SWOG S0354: a phase II trial of CNT0328, a monoclonal antibody against interleukin-6 (IL-6), in chemotherapy pre-treated patients (pts) with castration resistant prostate cancer (CRPC).
J Pinski, B Goldman, T Dorff, P Mack, P Lara, P vanVeldhuizen, D Quinn, MHA Hussain, IM Thompson. Accepted to the ASCO Annual Meeting Proceedings as a general poster.
Sunday, May 31, 2:00 – 6:00 PM, Level 2, West Hall C Poster no. J11, Abstract no. 5143

S9921
Southwest Oncology Group S9921: prolonged event free survival in high risk prostate cancer (PC) patients receiving adjuvant androgen deprivation.
Saturday, May 30, 3:30 – 3:45 PM, Level 3, Chapin Theater W320 Abstract no. 5009

**Lung**

S0124/ JCOG9511
Cisplatin (Cis) + irinotecan (CPT11) vs. Cis + etoposide (VP16) in extensive stage small cell lung cancer (E-SCLC): final comparative outcomes analysis of JCOG 9511 and SWOG 0124.
Monday, June 1, 11:00 AM – 12:00 PM, Level 2, West Hall E2 Poster no. 19, Abstract no. 8027

S0342/0536
Expression of EGFR protein and markers of epithelial-mesenchymal transformation (EMT) in cetuximab/chemotherapy-treated non-small cell lung cancer (NSCLC).
WA Franklin, DR Gandara, ES Kim, RS Herbst, J Moon, MW Redman, C Olsen, FR Hirsch, P Mack, K Kelly. Accepted to the ASCO Annual Meeting Proceedings as a general poster.
Monday, June 1, 1:00 – 5:00 PM, Level 2, West Hall C Poster no. R17, Abstract no. 11076

S0342/0536
KRAS mutation analysis in cetuximab-treated advanced stage non-small cell lung cancer (NSCLC): SWOG experience with S0342 and S0536.
PC Mack, WS Holland, M Redman, PN Lara, LJ Snyder, FR Hirsch, WA Franklin, ES Kim, RS Herbst, DR Gandara. Accepted to the ASCO Annual Meeting Proceedings as a poster discussion.
Monday, June 1, 11:00 AM – 12:00 PM, Level 2, West Hall E2 Poster no. 14, Abstract no. 8022

**Melanoma**

S0331
A phase II trial of imatinib mesylate in Merkel cell carcinoma (neuroendocrine carcinoma of the skin): A Southwest Oncology Group Study (S0331).
WE Samlowski, J Moon, RJ Tuthill, MC Heinrich, NS Balzer-Haas, SA Merl, RC DeConti, JA Thompson, LE Flaherty, VK Sondak.

S0528
Phase I evaluation of lapatinib and everolimus in patients (pts) with advanced malignancies: Southwest Oncology Group trial S0528.
CJ Hoban, A Hoering, TW Synold, V Chung, DR Gandara, AF Schott, L Kingsbury, D Lew, P LoRusso, SM Gadgeel. Accepted to the ASCO Annual Meeting Proceedings as a general poster.
Saturday, May 30, 8:00 AM – 12:00 PM, Level 2, West Hall C Poster no. H7, Abstract no. 3553

S0536
Carboplatin, paclitaxel, cetuximab and bevacizumab maintenance in advanced non-small cell lung cancer (NSCLC), a SWOG phase II study.
Monday, June 1, 11:00 AM – 12:00 PM, Level 2, West Hall E2 Poster no. 7, Abstract no. 8015
Accepted to the *ASCO Annual Meeting Proceedings* as a general poster.
Monday, June 1, 8:00 AM – 12:00 PM, Level 2, West Hall C
Poster no. F11, Abstract no. 9056

**Myeloma**

**S0120**
Role of T-cell immunity to embryonal stem (ES) cell antigen SOX2 in the progression of myeloma.
MV Dhodapkar, V Bolejack, J Shaughnessy, P Matthews, R Pickering, P Qu, A Hoering, J Crowley, B Barlogie.
Accepted to the *ASCO Annual Meeting Proceedings* as an oral presentation.
Sunday, May 31, 11:15 – 11:30 AM, Level 2, West Hall F1
Abstract no. 8522

**S0434**
A phase II trial of sorafenib in patients with relapsing and resistant multiple myeloma (MM) previously treated with bortezomib (S0434).
G Srkalovic, M Hussein, V Bolejack, A Hoering, J Zonder, B Barlogie.
Accepted to the *Journal of Clinical Oncology* as a published abstract.
Abstract no. e19517

**S9321**
Long-term follow-up of autotransplant (AT)-supported high-dose melphalan (hdm) for multiple myeloma (MM): update of Intergroup Francophone du Myelome (IFM), Southwest Oncology Group (SWOG), and Arkansas (ARK) Total Therapy (TT) trials.
B Barlogie, M Attal, J Crowley, J Harousseau.
Accepted to the *ASCO Annual Meeting Proceedings* as an oral presentation.
Sunday, May 31, 10:15 – 10:30 AM, Level 2, West Hall F1
Abstract no. 8519

**S9321**
Prognostic factor analyses of myeloma (MM) survival outcomes on intergroup trial S9321 (int 0141): examining whether different variables govern different time segments of survival.
Accepted to the *ASCO Annual Meeting Proceedings* as a general poster.
Saturday, May 30, 8:00 AM – 12:00 PM, Level 2, West Hall C
Poster no. T8, Abstract no. 8599

**Sarcoma**

**S0345**
Combined analysis of two phase II trials of imatinib in advanced dermatofibrosarcoma protuberans (DFSP).
S Schuetze, P Rutkowski, MM Van Glabbeke, C Rankin, BP Rubin, A Lazar, M Debiec-Rychter, H Gelderblom, P Hohenberger, AT van Oosterom.
Accepted to the *ASCO Annual Meeting Proceedings* as a poster discussion.
Saturday, May 30, 5:00 – 6:00 PM, Level 2, West Hall F5
Poster no. 9, Abstract no. 10520